The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Clinical observation of Tamsulosin hydrochloride Sustained Release Tablets combined with Qianliekang Tablets in treatment of type Ⅲ prostatitis
Author(s): 
Pages: 504-507
Year: Issue:  4
Journal: World Phytomedicines

Keyword:  Tamsulosin hydrochloride Sustained Release TabletsQianliekang Tabletstype Ⅲ prostatitis;
Abstract: Objective To explore the clinical effects of Tamsulosin hydrochloride Sustained Release Tablets combined with Qianliekang Tablets in treatment of typeⅢ prostatitis. Methods Patients(85 cases) with type Ⅲ prostatitis in Department of Urology Surgery of The People’s Hospital of Hechi from November 2014 to May 2015 were divided into control(42 cases) and treatment(43 cases) groups according to the random number table method. The patients in the control group were po administered with Qianliekang Tablets, 3 tablets/time, three times daily. The patients in the treatment group were po administered with Tamsulosin hydrochloride Sustained Release Tablets on the basis of control group, 1 tablet/time, once daily. The patients in two groups were treated for 6 weeks. After treatment, the efficacies were evaluated, and NIS-CPSI scores, white blood cell and p H value of prostatic fluid in two groups before and after treatment were compared. Results After treatment, the efficacies in the control and treatment groups were 66.67% and 86.05%, respectively, and there were differences between two groups(P < 0.05). After treatment, pain, urinary symptoms, quality of life and NIH-CPSI scores in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, white blood cell counts and p H values of prostatic fluid in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Tamsulosin hydrochloride Sustained Release Tablets combined with Qianliekang Tablets has clinical curative effect in treatment of typeⅢ prostatitis, can significantly reduce NIH-CPSI scores, higher security, which has a certain clinical application value.
Related Articles
No related articles found